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This study aimed to investigate whether supplementation with 12 mg×day−1 astaxanthin for 7 days can 22 
improve exercise performance and metabolism during a 40 km cycling time trial. 23 
Design 24 
A randomised, double-blind, crossover design was employed. 25 
Methods 26 
Twelve recreationally trained male cyclists (VO2peak: 56.5 ± 5.5 mL×kg−1×min−1, Wmax: 346.8 ± 38.4 W) 27 
were recruited. Prior to each experimental trial, participants were supplemented with either 12 mg×day−1 28 
astaxanthin or an appearance-matched placebo for 7 days (separated by 14 days of washout). On day 7 29 
of supplementation, participants completed a 40 km cycling time trial on a cycle ergometer, with indices 30 
of exercise metabolism measured throughout. 31 
Results 32 
Time to complete the 40 km cycling time trial was improved by 1.2 ± 1.7% following astaxanthin 33 
supplementation, from 70.76 ± 3.93 min in the placebo condition to 69.90 ± 3.78 min in the astaxanthin 34 
condition (mean improvement = 51 ± 71 s, p = 0.029, g = 0.21). Whole-body fat oxidation rates were 35 
also greater (+0.09 ± 0.13 g×min−1, p = 0.044, g = 0.52), and the respiratory exchange ratio lower (-0.03 36 
± 0.04, p = 0.024, g = 0.60) between 39-40 km in the astaxanthin condition. 37 
Conclusion 38 
Supplementation with 12 mg×day−1 astaxanthin for 7 days provided an ergogenic benefit to 40 km 39 
cycling time trial performance in recreationally trained male cyclists and enhanced whole-body fat 40 
oxidation rates in the final stages of this endurance-type performance event. 41 
Key words 42 




Dietary supplementation strategies that can modify substrate utilisation patterns during exercise have 45 
received widespread attention in the literature 1–3. One such supplement is astaxanthin, a liposoluble 46 
carotenoid usually supplemented through the intake of Haematococcus pluvialis-derived antioxidant 47 
products. Based upon research on mice, improvements in endurance performance are reported following 48 
3-5 weeks of astaxanthin intake 4–6. This is attributed to the potential for astaxanthin to protect and 49 
upregulate key metabolic enzymes, such as carnitine palmitoyltransferase 1 (CPT1) and 5’adenosine 50 
monophosphate-activated protein kinase (AMPK), that are implicated in the oxidation of fatty acids as 51 
a viable energy source 5,6. 52 
A similar ergogenic benefit was reported in trained cyclists, with 4 weeks of 4 mg×day−1 astaxanthin 53 
improving 20 km cycling time trial (TT) performance when compared to a placebo (mean improvement 54 
(MI) = astaxanthin: 121 s (5.1%) vs. placebo: 18 s (0.8%)) 7. Conversely, in a 1.0 h cycling TT an 55 
ergogenic benefit was not reported following a 4 week supplementation with either 20 mg×day−1 56 
astaxanthin (MI = 74 s (2.1%)) or a placebo (MI = 52 s (1.4%)) in trained cyclists or triathletes 8. 57 
Interestingly, astaxanthin did not influence measures of substrate utilisation obtained in either study 7,8. 58 
The absence of a metabolic effect may be explained by the use of a parallel group design in both studies 59 
7,8, with substrate utilisation rates known to vary considerably between individuals of a similar fitness 60 
demographic, even at the same absolute and relative exercise intensities 9,10. 61 
A 3-5 week supplementation strategy is seemingly advocated in mice-models when seeking to elicit the 62 
ergogenic potential of astaxanthin 4–6. In research on humans, one key methodological consistency to 63 
that of animal studies is the 3-5 week supplementation strategy implemented 7,8. Plasma astaxanthin 64 
concentrations are, however, reported to peak within the first week of intake, even when consumption 65 
is chronic. Rüfer et al. 11, for example, quantified the uptake of ~ 1.25 mg×day−1 astaxanthin in the 66 
plasma of 28 healthy males over a 4 week period and reported a peak in concentration following 6 days 67 
of intake 11. This finding enables shorter supplementation periods to be advocated, which in turn may 68 
allow the use of a randomised crossover design. 69 
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As such, the current study implements a 7 day supplementation period to ensure that participants could 70 
act as their own control, mitigating the potential impact inter-individual differences could have upon 71 
the outcome variable 12,13. A 40 km cycling TT was used as a reliable measure of endurance performance 72 
obtained during a distance that is common in competitive cycling events 14–16. Therefore, the aim of the 73 
current study was to investigate whether supplementation with 12 mg×day−1 astaxanthin for 7 days can 74 
improve exercise performance and metabolism during a 40 km cycling TT using a randomised crossover 75 
design. It was hypothesised that astaxanthin supplementation would improve cycling TT performance, 76 
an ergogenic effect underpinned by the ability of astaxanthin to enhance fat oxidation during exercise. 77 
Methods 78 
Twelve recreationally trained male cyclists (age: 27.5 ± 5.7 years, height: 1.78 ± 0.07 m, body mass: 79 
78.3 ± 7.6 kg, body fat: 13.7 ± 2.6%, VO2peak: 56.5 ± 5.5 mL×kg−1×min−1, Wmax: 346.8 ± 38.4 W) 80 
volunteered to participate in the study, with prior ethical approval attained from the institutional ethics 81 
committee (SPA-REC-2017-323). The term “recreationally trained cyclist” was deemed most 82 
appropriate for the sample recruited, as although performance criteria for a “trained cyclist” was met 83 
(VO2peak: 55-64.9 mL×kg−1×min−1; Wmax: 320-379 W), training load criteria was not (distance covered: 84 
60-290 km×week−1; cycling frequency ³ 3 times×week−1) 17. 85 
Supplementation with additional antioxidants/vitamins was not permitted alongside those provided in 86 
the current study, with a list of astaxanthin-rich foods to avoid also provided to limit the additional 87 
dietary intake of astaxanthin. Participants refrained from strenuous exercise and the consumption of 88 
alcohol and caffeine in the 24 h preceding each visit 18,19. Habitual dietary intake was maintained; 89 
however, participants entered the laboratory in a 4 h postprandial state, except for the ingestion of water 90 
to ensure euhydration. Compliance with the above procedures was checked via 24 h dietary recall, with 91 
dietary intake replicated prior to each trial. All participants visited the laboratory (temperature: 18.0 ± 92 
1.2 °C; pressure: 754.4 ± 8.8 mmHg, humidity 44.7 ± 3.5%) on four occasions (two preliminary trials 93 
and two experimental trials) at a similar time of day (± 1.0 h). A randomised, double-blind, crossover 94 
design was employed. 95 
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During the first preliminary visit participants completed a graded exercise test to volitional exhaustion 96 
using an electromagnetically-braked cycle ergometer (Lode Excalibur Sport, The Netherlands). The test 97 
commenced at 75.0 W, increasing by 30.0 W every 1 min until volitional exhaustion. Breath-by-breath 98 
expired air was collected for VO2peak determination and was defined as the highest 30 s average of VO2 99 
recorded during the test. A full familiarisation with the 40 km TT was then undertaken during a second 100 
preliminary visit to ensure participants were accustomed to procedures employed during each 101 
experimental trial. 102 
Prior to each experimental trial, participants supplemented with one of two randomly assigned 103 
supplements for 7 days, with supplementation separated by a 14-day washout period. Estimations were 104 
made based upon calculations that > 99.9% of a treatment is eliminated after a time period equivalent 105 
to 10 half-lives 20. Using a half-life of 15.9 ± 5.3 h 21, it was estimated that > 99.9% of total astaxanthin 106 
consumed would be eliminated following ~ 7 days of washout. As this was an estimation, a more 107 
conservative 14-day washout period was decided upon in the current study. Supplementation consisted 108 
of either 12 mg×day−1 astaxanthin (AstaReal®, Sweden) or an appearance-matched placebo with no 109 
viable constituents (AstaReal®, Sweden). Participants ingested two capsules daily (one morning and 110 
one evening), with compliance ensured via daily text message reminders and a pill count post-ingestion. 111 
To ensure the study remained double-blind, each supplement was assigned a randomised 112 
alphanumerical code until after data analysis was complete. 113 
Each experimental trial required participants to undertake a 5 min warm-up before completing a 40 km 114 
TT on a Velotron RacermateÔ cycle ergometer (Velotron, USA). Preferred frame geometry was 115 
selected and replicated between trials. Information regarding cadence, gear and distance covered was 116 
received, with no other information or external encouragement provided. Participants were permitted 117 
to drink water ad libitum during the first experimental trial, with the volume of water consumed 118 
recorded and kept constant during the second experimental trial. Time to complete and mean power 119 
were recorded for both the total distance and for each 10 km quartile during the TT. Heart rate (HR), 120 
ratings of fatigue (ROF) 22 and ratings of perceived exertion (RPE) 23 for the whole-body (RPEO) and 121 
the lower limbs (RPEL) were measured every 10 km. A finger prick capillary blood sample was taken 122 
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at rest and every 10 km during the TT to determine blood lactate (Lactate Pro 2, Japan), glucose 123 
(Hemocue, Sweden) and triglycerides (Reflotron, USA). Breath-by-breath expired air was obtained 124 
during the 10th, 20th, 30th and 40th km of the TT. Respiratory gas data were then used to calculate whole-125 
body fat and carbohydrate oxidation rates (FATox and CHox, respectively) using the method of 126 
Jeukendrup and Wallis 24. 127 
As assumptions of normality and homogeneity were met, a paired t-test was used to compare differences 128 
in performance time and mean power between conditions, and to determine whether a trial order effect 129 
was present. A two-way [condition x time] analysis of variance (ANOVA) was used to determine 130 
differences in performance, respiratory and perceptual variables, blood metabolites and HR. Post-hoc 131 
analysis was performed with a Bonferroni adjustment. Effect sizes were calculated using Hedge’s g and 132 
were interpreted as trivial (< 0.20), small (0.20-0.49), moderate (0.50-0.79) or large (≥ 0.80) 25. 133 
Confidence intervals (CI) (± 95.0%) were also calculated and are reported where necessary. Descriptive 134 
data are displayed as mean ± standard deviation (SD). Statistical analysis was conducted using a 135 
statistical software package (SPSS, Version 25, USA), with significance accepted at p < 0.05. 136 
Results 137 
Time to complete the 40 km TT (Figure 1a) was improved from 70.76 ± 3.93 min in the placebo 138 
condition to 69.90 ± 3.78 min in the astaxanthin condition, which equates to a 1.2 ± 1.7% improvement 139 
(MI = 51 ± 71 s, 95.0% CI = 6-96 s, p = 0.029, g = 0.21). Mean power (Figure 1c) was also improved 140 
from 213.8 ± 29.0 W in the placebo condition to 219.9 ± 28.7 W in the astaxanthin condition, which 141 
equates to a 2.8 ± 4.1% improvement (MI = 6.1 ± 9.5 W, 95.0% CI = 0.1-12.1 W, p = 0.047, g = 0.20). 142 
No trial order was present for performance time (p = 0.993, g = 0.04) or mean power (p = 0.996, g = 143 
0.02). There was also no [condition x time] interaction observed across each 10 km quartile for either 144 
performance time (p = 0.158; Figure 1b) or mean power (p = 0.242; Figure 1d), suggesting that the 145 
general pacing profile of the 40 km TT was similar across conditions. 146 
A [condition x time] interaction was observed for FATox (p = 0.037), whereby FATox was greater 147 
between 39-40 km following astaxanthin supplementation (Figure 2c), increasing from 0.13 ± 0.04 148 
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g×min−1 in the placebo condition to 0.22 ± 0.05 g×min−1 in the astaxanthin condition (+0.09 ± 0.13 149 
g×min−1, 95.0% CI = 0.00-0.17 g×min−1, p = 0.044, g = 0.52). A similar [condition x time] interaction 150 
was also observed for the respiratory exchange ratio (RER) (p = 0.007), whereby RER was lower 151 
between 39-40 km following astaxanthin supplementation (Figure 2a), decreasing from 0.99 ± 0.02 in 152 
the placebo condition to 0.96 ± 0.01 in the astaxanthin condition (-0.03 ± 0.04, 95.0% CI = -0.01 to -153 
0.06, p = 0.024, g = 0.60). For CHox a [condition x time] interaction was present (p = 0.037), with 154 
CHox greater at 39-40 km in both conditions (p < 0.045). There were, however, no differences reported 155 
between conditions for CHox at any time point during the TT (p ³ 0.118; Figure 2e). 156 
Lactate (Figure 2b) was increased above baseline throughout the TT (p ≤ 0.001) and was greater at 40 157 
km compared to 30 km (p = 0.002). Glucose (Figure 2f) was lower throughout the TT when compared 158 
to baseline (p ≤ 0.003), and triglycerides (Figure 2d) were increased above baseline at 30 km (p = 0.027) 159 
and 40 km (p = 0.002), as well as being greater at 40 km than at any other time point (p ≤ 0.003). There 160 
were no differences between conditions for each of these blood metabolites (p ³ 0.346). 161 
Ratings of fatigue (p < 0.001), RPEO (p < 0.001) and RPEL (p < 0.001) all increased progressively over 162 
time with no effect of condition (p ³ 0.131). A main effect of time was also present for HR (p < 0.001) 163 
and VO2 (p < 0.001) in both conditions (p ³ 0.338), with HR greater at 40 km than at each previous time 164 
point (p ≤ 0.001) and VO2 greater at 30 km than at 20 km (p = 0.029) and at 40 km when compared to 165 
each previous time point (p ≤ 0.002) (Table 1). 166 
Discussion 167 
The current investigation is the first to demonstrate an increase in whole-body fat oxidation (FATox) 168 
and a corresponding reduction in RER during endurance exercise in humans supplementing with 169 
astaxanthin. This study also reports a small, yet significant, ergogenic benefit from 12 mg×day−1 170 
astaxanthin supplementation for 7 days in recreationally trained male cyclists completing a 40 km 171 
cycling TT. This equates to a mean 51 s (1.2%) time improvement when compared to the placebo. 172 
The performance findings of this study are, therefore, consistent with those reported by Earnest et al. 7, 173 
as 4 weeks of 4 mg×day−1 astaxanthin improved 20 km cycling TT performance in trained male cyclists 174 
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7. Furthermore, the 121 s time improvement (5.1%) reported in the astaxanthin group was greater than 175 
the corresponding 18 s improvement (0.8%) reported in the placebo, suggesting a treatment effect was 176 
present 7. In contrast, an ergogenic benefit was not reported during a 1.0 h cycling TT in trained male 177 
cyclists or triathletes following 4 weeks of supplementation with either 20 mg×day−1 astaxanthin (MI = 178 
74 s (2.1%)) or a placebo (MI = 52 s (1.4%)) 8. Although there is no clear explanation for the disparity 179 
between the two studies 7,8, neither Earnest et al. 7 nor Res et al. 8 reported differences in substrate 180 
utilisation during exercise. Four weeks of 4 mg×day−1 astaxanthin supplementation, for example, did not 181 
influence measures of RER, CHox or FATox obtained during a 2 h submaximal cycle at 5.0% below 182 
the lactate threshold 7. Likewise, 20 mg×day−1 astaxanthin for 4 weeks did not influence measures of 183 
RER, CHox or FATox obtained during the completion of a 1.0 h steady-state cycle at 50.0% Wmax 8. As 184 
such, the increase in FATox and the decrease in RER reported in the latter stages of exercise in the 185 
current study are in contrast with previous research 7,8. 186 
The shorter 7-day supplementation strategy implemented in the current study, which enabled the use of 187 
a randomised crossover design, may provide a methodological insight as to why a metabolic effect of 188 
astaxanthin has been observed. In previous research the application of a prolonged supplementation 189 
strategy has required the use of a parallel group design 7,8. A major strength of the current study is, 190 
therefore, the ability to implement a randomised crossover design as this enabled each participant to act 191 
as their own control, minimising the potential impact subtle differences in participant characteristics 192 
and individual responses to astaxanthin could have upon the outcome variable 12,13. This would have 193 
improved the statistical power of the study and may have increased the ability to detect subtle 194 
differences in substrate utilisation during exercise.  195 
The current study also measured substrate utilisation during the completion of an ecologically valid 196 
performance event and not during a single-intensity, steady-state preload 7,8. Therefore, the metabolic 197 
measures obtained during the 40 km TT may have more accurately reflected the ergogenic mechanism 198 
by which astaxanthin is purported to improve performance during self-paced, best effort endurance 199 
events. Conversely, the change in FATox and RER reported between 39-40 km may be attributable to 200 
an increased utilisation of carbohydrates in the placebo condition, with a seemingly greater increase in 201 
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power (+6.6%) observed from 20-30 km to 30-40 km when compared to the astaxanthin condition 202 
(+3.0%). No differences were, however, reported in the general pacing profile of the TT between 203 
conditions, with indices of CHox, blood glucose and/or lactate also not different between conditions at 204 
any time point. Furthermore, the reported change in FATox between 39-40 km also occurred at the 205 
same relative exercise intensity (astaxanthin: 46.3 ± 8.6 mL×kg−1×min−1 vs. placebo: 45.2 ± 7.4 206 
mL×kg−1×min−1), providing further evidence to an increased utilisation of fat at this time point. 207 
Possible explanations for the metabolic effect of astaxanthin are received from previous exploratory 208 
research. Astaxanthin, for example, accumulates in the mitochondrial membrane following 209 
consumption where it is suggested to indirectly enhance FATox through protecting CPT1 from 210 
oxidative modifications during exercise 5,26,27. The expression of AMPK is also reported to be 211 
upregulated following astaxanthin intake 6.  As a key enzyme in skeletal muscle metabolism, AMPK is 212 
implicated in the stimulation of fatty acid oxidation; the transportation of fatty acids into the 213 
mitochondria, potentially through the intercalation of CPT1 and fatty acid translocase/CD36; as well as 214 
the upregulation of transcription factors, such as peroxisome proliferator-activated receptor-γ 215 
coactivator-1α (PGC-1α), that are known to promote mitochondrial biogenesis and control 216 
mitochondrial oxidative capacity 28. As this mechanistic insight is exclusively from mice-models, future 217 
exploratory research is necessary to elucidate similar mechanistic information in exercising humans. 218 
Finally, as astaxanthin uptake was not quantified in the current investigation, the 7 day supplementation 219 
strategy was informed by previous literature 11. Nevertheless, an ergogenic and metabolic effect of 220 
astaxanthin was demonstrated following this 7-day strategy, thus an exploration of the human 221 
pharmacokinetics of astaxanthin is clearly required so that an optimal supplementation strategy can be 222 
designed and implemented for future practice within this research area. Another potential limitation is 223 
that intra-individual variation in performance was also inferred from previous literature that investigated 224 
the reproducibility of the 40 km TT in trained cyclists (0.9 ± 0.7%) 15. Although greater intra-individual 225 
variations of 3.4% are reported following repeated TTs of a similar duration (~ 1.0 h) 29, it should be 226 
noted that caution is suggested when comparing pacing and performance between time- and distance-227 
based TTs 30. As such, the intra-individual variation of 0.9 ± 0.7% may be more appropriate for the 228 
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current study. To ensure that changes in performance (1.2 ± 1.7% in the current study) can be confirmed 229 
as meaningful, future research should seek to calculate intra-individual variation within the actual 230 
sample recruited. 231 
Conclusion 232 
Supplementation with 12 mg×day−1 astaxanthin for 7 days provided an ergogenic benefit to 40 km 233 
cycling TT performance in recreationally trained male cyclists and enhanced whole-body fat oxidation 234 
in the final stages of this endurance-type performance event. Future research should seek to determine 235 
an optimal supplementation strategy for astaxanthin intake based on pharmacokinetics, while exploring 236 
the underlying mechanistic factors by which astaxanthin is purported to exert its ergogenic effect in 237 
exercising humans. 238 
Practical Implications 239 
• The ergogenic potential of astaxanthin may be elicited following a shorter duration intake than 240 
previously advocated. 241 
• The outcomes of this study suggest that 12 mg×day−1 astaxanthin may provide an ergogenic 242 
benefit and promote fat oxidation during endurance-type cycling TTs. 243 
• To enable the successful application of astaxanthin in sport nutrition future investigations 244 
should aim to determine an optimal supplementation strategy for astaxanthin intake in 245 
exercising humans. 246 
References 247 
1. Hawley, J. A., Brouns, F. & Jeukendrup, A. Strategies to enhance fat utilisation during 248 
exercise. Sports Med. 25, 241–57 (1998). 249 
2. Yeo, W. K., Carey, A. L., Burke, L., Spriet, L. L. & Hawley, J. A. Fat adaptation in well-250 
trained athletes: effects on cell metabolism. Appl. Physiol. Nutr. Metab. 36, 12–22 (2011). 251 
3. Burke, L. M. Re-Examining High-Fat Diets for Sports Performance: Did We Call the ‘Nail in 252 
the Coffin’ Too Soon? Sport. Med. 45, 33–49 (2015). 253 
11 
 
4. Ikeuchi, M., Koyama, T., Takahashi, J. & Yazawa, K. Effects of astaxanthin supplementation 254 
on exercise-induced fatigue in mice. Biol. Pharm. Bull. 29, 2106–10 (2006). 255 
5. Aoi, W. et al. Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect 256 
of oxidative CPT I modification. Biochem. Biophys. Res. Commun. 366, 892–897 (2008). 257 
6. Aoi, W., Maoka, T., Abe, R., Fujishita, M. & Tominaga, K. Comparison of the effect of 258 
nonnesterified and esterified astaxanthins on endurance performance in mice. J. Clin. 259 
Biochem. Nutr 62, 161–166 (2018). 260 
7. Earnest, C. P., Lupo, M., White, K. M. & Church, T. S. Effect of astaxanthin on cycling time 261 
trial performance. Int. J. Sports Med. 32, 882–8 (2011). 262 
8. Res, P. T. et al. Astaxanthin Supplementation Does Not Augment Fat Use or Improve 263 
Endurance Performance. Med. Sci. Sport. Exerc. 45, 1158–1165 (2013). 264 
9. Achten, J., Gleeson, M. & Jeukendrup, A. E. Determination of the exercise intensity that elicits 265 
maximal fat oxidation. Med. Sci. Sports Exerc. 34, 92–7 (2002). 266 
10. Venables, M. C., Achten, J. & Jeukendrup, A. E. Determinants of fat oxidation during exercise 267 
in healthy men and women: a cross-sectional study. J. Appl. Physiol. 98, 160–7 (2005). 268 
11. Rüfer, C. E., Moeseneder, J., Briviba, K., Rechkemmer, G. & Bub, A. Bioavailability of 269 
astaxanthin stereoisomers from wild (Oncorhynchus spp.) and aquacultured (Salmo salar) 270 
salmon in healthy men: a randomised, double-blind study. Br. J. Nutr. 99, 1048–54 (2008). 271 
12. Cleophas, T. J. M. & de Vogel, E. M. Crossover studies are a better format for comparing 272 
equivalent treatments than parallel‐group studies. Pharm. World Sci. 20, 113–117 (1998). 273 
13. Burke, L. M. & Peeling, P. Methodologies for Investigating Performance Changes With 274 
Supplement Use. Int. J. Sport Nutr. Exerc. Metab. 28, 159–169 (2018). 275 
14. Palmer, G., Dennis, S., Noakes, T. & Hawley, J. Assessment of the Reproducibility of 276 




15. Laursen, P. B., Shing, C. M. & Jenkins, D. G. Reproducibility of a Laboratory-Based 40-km 279 
Cycle Time-Trial on a Stationary Wind-Trainer in Highly Trained Cyclists. Int. J. Sports Med. 280 
24, 481–485 (2003). 281 
16. Currell, K. & Jeukendrup, A. E. Validity, Reliability and Sensitivity of Measures of Sporting 282 
Performance. Sport. Med. 38, 297–316 (2008). 283 
17. De Pauw, K. et al. Guidelines to Classify Subject Groups in Sport-Science Research. 284 
International Journal of Sports Physiology and Performance 8, (2013). 285 
18. Rosenberg, K. et al. The effect of alcohol on resting metabolic rate. Br. J. Nutr. 40, 293 286 
(1978). 287 
19. Westerterp-Plantenga, M., Diepvens, K., Joosen, A. M. C. P., Bérubé-Parent, S. & Tremblay, 288 
A. Metabolic effects of spices, teas, and caffeine. Physiol. Behav. 89, 85–91 (2006). 289 
20. Saha, N. Clinical Pharmacokinetics and Drug Interactions. Pharm. Med. Transl. Clin. Res. 81–290 
106 (2018). doi:10.1016/B978-0-12-802103-3.00006-7 291 
21. Mercke Odeberg, J., Lignell, A., Pettersson, A. & Höglund, P. Oral bioavailability of the 292 
antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. 293 
Eur. J. Pharm. Sci. 19, 299–304 (2003). 294 
22. Micklewright, D., St Clair Gibson, A., Gladwell, V. & Al Salman, A. Development and 295 
Validity of the Rating-of-Fatigue Scale. Sport. Med. 47, 2375–2393 (2017). 296 
23. Borg, G. A. Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc. 14, 377–81 297 
(1982). 298 
24. Jeukendrup, A. E. & Wallis, G. A. Measurement of Substrate Oxidation During Exercise by 299 
Means of Gas Exchange Measurements. Int. J. Sports Med. 26, S28–S37 (2005). 300 
25. Cohen, J. Statistical power analysis for the behavioral sciences. (L. Erlbaum Associates, 301 
1988). 302 
26. Wolf, A. M. et al. Astaxanthin protects mitochondrial redox state and functional integrity 303 
13 
 
against oxidative stress. J. Nutr. Biochem. 21, 381–389 (2010). 304 
27. Kidd, P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging 305 
potential. Altern. Med. Rev. 16, 355–64 (2011). 306 
28. Thomson, D. M. & Winder, W. W. AMP-activated protein kinase control of fat metabolism in 307 
skeletal muscle. Acta Physiol. (Oxf). 196, 147–54 (2009). 308 
29. Jeukendrup, A., Saris, W. H. M., Brouns, F. & Kester, A. D. M. A new validated endurance 309 
performance test. Med. Sci. Sports Exerc. 28, 266–270 (1996). 310 
30. Abbiss, C. R., Thompson, K. G., Lipski, M., Meyer, T. & Skorski, S. Difference in pacing 311 
between time- and distance-based time trials in trained cyclists. Int. J. Sports Physiol. Perform. 312 





Table 1. Mean ± SD. Physiological and perceptual results. δ denotes a significant difference to the previous time point, † denotes a significant difference to all 316 
previous time points (p < 0.05). 317 
Variable Astaxanthin Placebo 
 10 km 20 km 30 km 40 km 10 km 20 km 30 km 40 km 
VO2 (mL×kg−1×min−1) 41.0 ± 7.6 40.1 ± 7.6 40.6 ± 8.2 δ 46.3 ± 8.6 † 39.6 ± 5.8 39.2 ± 6.9 41.1 ± 6.6 δ 45.2 ± 7.4 † 
HR (beats×min−1) 153 ± 10 155 ± 9 156 ± 10 171 ± 10 † 153 ± 13 154 ± 11 156 ± 11 171 ± 9 † 
ROF 3.7 ± 1.5 5.2 ± 1.3 δ 6.6 ± 1.3 δ 8.1 ± 1.6 † 3.2 ± 1.2 5.0 ± 1.5 δ 5.8 ± 1.7 δ 7.6 ± 1.8 † 
RPEO 13.8 ± 1.4 14.9 ± 1.4 δ 16.3 ± 1.4 δ 18.1 ± 1.3 † 13.3 ± 1.7 14.8 ± 1.5 δ 16.2 ± 1.5 δ 18.3 ± 1.8 † 






Figure 1. Mean ± SD. Individual values for performance time (a) and power output (c) during the 40 321 
km time trial following each condition. Data for 10 km quartile performance times (b) and power 322 
outputs (d) are also displayed as mean (± SD) for each condition. * denotes a significant difference 323 




Figure 2. Mean ± SD. Respiratory measures of the respiratory exchange ratio (RER) (a), whole-body 326 
fat oxidation rates (FATox) (c), whole-body carbohydrate oxidation rates (CHox) (e), and blood 327 
metabolites lactate (b), triglycerides (d) and glucose (f) obtained over the duration of each 40 km time 328 
trial. * denotes a significant difference between conditions, # denotes a significant difference to 329 
baseline, δ denotes a significant difference to the previous time point, † denotes significant difference 330 
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